Adjuvant Nivolumab Improved DFS in Esophageal and GEJ Cancers
Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.
Andrea S. Blevins Primeau, PhD, MBA
Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.
